Skip to main content
Equibles
ZLAB logo

ZLAB · Zai Lab Ltd · Webcasts, Transcripts & Audio

Track ZLAB — free

Use ZLAB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ZLAB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$24.33 -1.17 (-4.59%) At close · Oct 2
Rebalance outlook locked
Customer concentration — top customer 18% of receivables

One customer — 18% of receivables (As of June 30, 2026)

“As of June 30, 2026, our largest customer accounted for approximately 18% of our total accounts receivable collectively.”
View the 10-Q filed Aug 6, 2026
Market Cap
$2.88B
Shares
112.27M
Volume · Oct 2 951.85K Avg daily vol (3M) 947.97K

Zai Lab Ltd Webcasts

Earnings calls, investor updates, investor days and conferences for Zai Lab Ltd (ZLAB), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲33.5% $57.54M −$161.19M '22 Q3 22-11-09 ▲42.4% $62.60M −$61.77M '22 Q4 23-03-01 ▲34.4% $62.80M −$49.14M '23 Q1 23-05-09 ▲42.9% $68.86M −$120.89M '23 Q2 23-08-07 ▲20.3% $69.23M −$69.15M '23 Q3 23-11-07 ▲5.2% $65.83M −$95.43M '23 Q4 24-02-27 ▲38.8% $87.15M −$53.47M '24 Q1 24-05-08 ▲45.9% $100.50M −$80.28M '24 Q2 24-08-06 ▲47.7% $102.27M −$41.67M '24 Q3 24-11-12 ▲65.7% $109.07M −$81.68M '24 Q4 25-02-27 ▲22.2% $106.49M −$48.44M '25 Q1 25-05-08 ▲9.4% $109.98M −$40.73M '25 Q2 25-08-07 ▲13.5% $116.09M −$35.96M '25 Q3 25-11-06 ▲17% $127.60M −$50.41M '25 Q4 26-02-26 ▼6.5% $99.61M −$51.02M '26 Q1 26-05-07 LATEST ▼3.3% $106.31M −$50.83M '26 Q2 26-08-06
Earnings call
FY26 · Q2
2026-08-06
Zai Lab Ltd (ZLAB) Q2 2026 Earnings Call Transcript
Confident tone Regulatory pathway and approval timelines ZL1503 IL-13/IL-31 bispecific for atopic dermatitis Zositan/ZOSI DLL3 ADC in small cell lung cancer
Revenue
$106.31M
▼ 3.3% YoY
Diluted EPS
$-0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Zai Lab Ltd (ZLAB) Q1 2026 Earnings Call Transcript
Confident tone Global collaborations with Amgen and Boehringer Ingelheim ZL1503 IL-13/IL-31 bi-specific in atopic dermatitis Pipeline R&D engine and AI/data-driven approaches
Revenue
$99.61M
▼ 6.5% YoY
Diluted EPS
$-0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Zai Lab Ltd (ZLAB) Q4 2025 Earnings Call Transcript
Confident tone Global pipeline / zoci DLL3 ADC Execution risk and Phase III design uncertainties KarXT (xanomeline-trospium) launch in China
Revenue
$127.60M*
▲ 17% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Zai Lab Ltd (ZLAB) Q3 2025 Earnings Call
Confident tone ZL1503 immunology / atopic dermatitis Pivotal/registrational milestones and BLA submission Regional immunology and partner updates (VivGuard, Vertex)
Revenue
$116.09M
▲ 13.5% YoY
Diluted EPS
$-0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Zai Lab Ltd (ZLAB) Q2 2025 Earnings Call Transcript
Confident tone VYVGART commercial momentum and label expansion Global pipeline and DLL3 ADC (ZL-1310) Near-term regulatory milestones and launches
Revenue
$109.98M
▲ 9.4% YoY
Diluted EPS
$-0.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Zai Lab Ltd (ZLAB) Q1 2025 Earnings Call Transcript
Confident tone VYVGART franchise growth FDA regulatory environment uncertainty Global pipeline / ZL-1310 DLL3 ADC
Revenue
$106.49M
▲ 22.2% YoY
Diluted EPS
$-0.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Zai Lab Ltd (ZLAB) Q4 2024 Earnings Call Transcript
Confident tone VYVGART Launch and Expansion ZL-1310 DLL3 ADC in Small Cell Lung Cancer Global Pipeline and R&D Progress
Revenue
$109.07M*
▲ 65.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Zai Lab Ltd (ZLAB) Q3 2024 Earnings Call Transcript
Confident tone VYVGART commercial launch and growth Global pipeline expansion and internal R&D Late-stage regulatory approvals and upcoming launches
Revenue
$102.27M
▲ 47.7% YoY
Diluted EPS
$-0.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Zai Lab Ltd (ZLAB) Q2 2024 Earnings Call Transcript
Confident tone VYVGART commercial launch R&D pipeline progress ZEJULA and other commercial products
Revenue
$100.50M
▲ 45.9% YoY
Diluted EPS
$-0.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Zai Lab Ltd (ZLAB) Q1 2024 Earnings Call Transcript
Confident tone VYVGART launch and uptake Future launches (KarXT, TIVDAK, bemarituzumab, CIDP) Global pipeline and business development
Revenue
$87.15M
▲ 38.8% YoY
Diluted EPS
$-0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Zai Lab Ltd (ZLAB) Q4 2023 Earnings Call Transcript
Confident tone VYVGART launch and NRDL inclusion Revenue growth and 2024 outlook Neuroscience pipeline and label expansion
Revenue
$65.83M*
▲ 5.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Zai Lab Ltd (ZLAB) Q3 2023 Earnings Call Transcript
Revenue
$69.23M
▲ 20.3% YoY
Diluted EPS
$-0.07
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Zai Lab Ltd (ZLAB) Q2 2023 Earnings Call Transcript
Revenue
$68.86M
▲ 42.9% YoY
Diluted EPS
$-0.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Zai Lab Ltd (ZLAB) Q1 2023 Earnings Call Transcript
Revenue
$62.80M
▲ 34.4% YoY
Diluted EPS
$-0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-01
Zai Lab Ltd (ZLAB) Q4 2022 Earnings Call Transcript
Revenue
$62.60M*
▲ 42.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Zai Lab Ltd (ZLAB) Q3 2022 Earnings Call Transcript
Revenue
$57.54M
▲ 33.5% YoY
Diluted EPS
$-0.17
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Zai Lab Ltd (ZLAB) Q2 2022 Earnings Call Transcript
Revenue
$48.18M
▲ 30.4% YoY
Diluted EPS
$-0.14
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Zai Lab Ltd (ZLAB) Q1 2022 Earnings Call Transcript
Revenue
$46.72M
▲ 132.4% YoY
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Zai Lab Ltd (ZLAB) Q4 2021 Earnings Call Transcript
Revenue
$43.96M
▲ 191.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Zai Lab Ltd (ZLAB) Q3 2021 Earnings Call Transcript
Revenue
$43.10M
▲ 194.2% YoY
Diluted EPS
$-0.10
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Zai Lab Ltd (ZLAB) Q2 2021 Earnings Call Transcript
Revenue
$36.94M
▲ 235.9% YoY
Diluted EPS
$-0.18
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Zai Lab Ltd (ZLAB) Q1 2021 Earnings Call Transcript
Revenue
$20.10M
▲ 144.6% YoY
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-01
Zai Lab Ltd (ZLAB) Q4 2020 Earnings Call Transcript
Revenue
$15.09M
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q2
2020-06-30
Zai Lab Ltd (ZLAB) Q2 2020 Earnings Call Transcript
Revenue
$10.99M
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–24 of 24 webcasts
Key facts CIK 1704292 CUSIP 98887Q104 13F (30d) 2 filings 2 filers Visit website Investor relations